Table 1 Sample characteristics (n = 343)
Characteristics | Mean ± SD / n (%) |
|---|---|
Age (years) | 55.15 ± 9.36 |
Race | |
Chinese | 269 (78.4) |
Non-Chinese Asians | 31 (9.0) |
Caucasian | 43 (12.5) |
Gender | |
Female | 256 (74.6) |
Male | 87 (25.4) |
Cancer diagnosis | |
Gynecological (ovary, cervix, endometrium, genital tract) | 45 (13.1) |
Lung | 48 (14.0) |
Head and neck | 30 (8.7) |
Breast | 174 (50.7) |
Urinary tract (prostate, bladder, uterus) | 17 (5.0) |
Gastrointestinal (esophagus, pancreas, stomach, bile duct, colon-rectum) | 29 (8.5) |
Cancer stage | |
Stage I | 52 (15.2) |
Stage II | 99 (28.9) |
Stage III | 116 (33.8) |
Stage IV | 76 (22.2) |
Treatment intent | |
Radical (adjuvant) | 199 (58.0) |
Radical (neoadjuvant) | 51 (14.9) |
Radical (concurrent) | 30 (8.7) |
Palliative | 63 (18.4) |
Chemotherapy agents | |
Docetaxel | 122 (35.6) |
Paclitaxel | 33 (9.6) |
Cisplatin | 42 (12.2) |
Carboplatin | 8 (2.3) |
Oxaliplatin | 9 (2.6) |
Carboplatin + Paclitaxel | 50 (14.6) |
Carboplatin + Docetaxel | 29 (8.5) |
Vinorelbine | 31 (9.0) |
Xelox | 19 (5.5) |
Diabetes History | |
Yes | 54 (15.7) |